MENU
CLOSE

New 12-Month Preclinical Milestone in Regenerative Aesthetics

Conexeu completed a 12-month multi-tissue preclinical program in aesthetics. The program met its pre-defined objectives.

Black-arrow
Home
CXU Science
Our Platform +
Resources
Investors
About Conexeu
Contact Us
Platform
Aesthetics
Strategy
Wound Care
Oral Health
Animal Health
3D Tissue
3D B.R.E.A.S.T.
Dermatology Times

Dermatology Times Interview, Part 1: Conexeu Sciences Advances Bio-Regenerative ECM Platform for Structural Tissue Restoration

Conexeu is developing an injectable, thermosensitive ECM scaffold to remodel skin after rapid weight loss, aiming beyond fillers to restore tissue structure.

Conexeu
Architecting Bioregeneration™

Read and watch Part 1 of Miles Harrison and Brian Pilcher's interview with Dermatology Times here: https://www.dermatologytimes.com/view/conexeu-sciences-advances-bio-regenerative-ecm-platform-for-structural-tissue-restoration

‍

At the intersection of regenerative medicine and aesthetic dermatology, a new approach to tissue restoration is being developed by Conexeu Sciences, which is investigating a bio-regenerative platform designed to restore the extracellular matrix (ECM), according to Miles Harrison, president and CEO, and Brian Pilcher, PhD, chief medical officer.

News and Media

Stay in the know about Conexeu, CXU and the future of regenerative science.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
This is some text inside of a div block.
Dermatology Times
August 4, 2026
Dermatology Times Interview, Part 1: Conexeu Sciences Advances Bio-Regenerative ECM Platform for Structural Tissue Restoration
Conexeu is developing an injectable, thermosensitive ECM scaffold to remodel skin after rapid weight loss, aiming beyond fillers to restore tissue structure.
Conexeu
August 18, 2026
Conexeu Sciences Sees a New Category Forming in Medical Aesthetics as Research Turns to Regeneration
Peer-reviewed research points to the extracellular matrix, the framework that holds tissue together, as central to that work. More than a decade of research has gone into Conexeu’s CXU™ Platform
Conexeu
Dermatology Times
August 5, 2026
Dermatology Times Interview, Part 2: From Wound Care to Aesthetics
Miles Harrison and Chief Medical Officer Brian Pilcher, PhD, continue their Dermatology Times conversation on whether bio-regeneration is the future of wound repair and medical aesthetics.
Conexeu
Yahoo Finance
August 3, 2026
Next GLP-1 Billion-Dollar Market: Fireside Chat with Conexeu Sciences CEO Miles Harrison
IPO Edge examines where the next billion-dollar GLP-1 opportunity sits, and how Conexeu Sciences is positioning its CXU™ platform against it.
Conexeu
Dermatology Times
August 4, 2026
Dermatology Times Interview, Part 1: Conexeu Sciences Advances Bio-Regenerative ECM Platform for Structural Tissue Restoration
Conexeu is developing an injectable, thermosensitive ECM scaffold to remodel skin after rapid weight loss, aiming beyond fillers to restore tissue structure.
Conexeu
TheStreet Pro
July 14, 2026
The Street Pro
CEO Miles Harrison breaks down how Conexeu's preclinical-stage platform targets wound care, medical aesthetics and a GLP-1-driven opportunity most investors are missing.
Conexeu
Practical Investing
July 14, 2026
Practical Investing
A follow-up Practical Investing segment on Conexeu Sciences (Nasdaq: CNXU) and the GLP-1-driven tissue-restoration opportunity.
Conexeu
Rick Orford
July 20, 2026
Rick Orford
CEO Miles Harrison on why the CXU™ platform is designed to create a biological scaffold the body can rebuild into, rather than replacing tissue with fillers or implants.
Conexeu
Progress, Potential and Possibilities
July 7, 2026
Progress Potential and Possibilities Claudia Interview
For decades, mastectomy patients have chosen between permanent implants and transplanted tissue. Dr. Claudia Chavez-Munoz discusses a third possibility — regenerating what was lost.
Conexeu
Investor TV
April 23, 2026
Investor TV GLP1
Millions are losing weight with GLP-1 drugs. What happens after? A look at the changes in facial structure, skin quality and tissue support now being observed.
Conexeu
Investor TV
May 14, 2026
Investor TV Panel Paul GLP1
Rapid, medication-driven weight loss goes far beyond the scale. A panel on the volume loss, skin laxity and structural tissue change the current aesthetic toolkit was never designed to address.
Conexeu
Stocks to Watch
May 27, 2026
Stocks To Watch Miles Interview
President and CEO Miles Harrison on how Conexeu's platform could address the tissue-restoration demand created by GLP-1 weight-loss medications.
Conexeu
Stocks to Watch
June 3, 2026
Stocks To Watch BREAST Interview
Reconstruction is being redefined: Conexeu Sciences discusses B.R.E.A.S.T.™, a new approach designed to advance breast reconstruction following mastectomy.
Conexeu
ZipTrader
June 7, 2026
Zip Trader
ZipTrader looks at Conexeu Sciences (Nasdaq: CNXU) and its regenerative tissue platform.
Conexeu
Investor TV
May 4, 2026
Investor TV Panel Claudia
GLP-1 therapies are reshaping more than weight loss. Dr. Claudia Chavez-Munoz joins a panel on facial volume loss, skin laxity and broader changes in tissue health.
Conexeu
Investor TV
July 9, 2026
Investor TV Webinar
President and CEO Miles Harrison discusses Conexeu's expansion into regenerative aesthetics, the CXU™ platform, the WFIRM collaboration, manufacturing scale-up and upcoming milestones.
Conexeu
Practical Investing
June 30, 2026
Practical Investing
Practical Investing profiles Conexeu Sciences (Nasdaq: CNXU) and its regenerative tissue platform.
Conexeu
Conexeu Sciences
June 22, 2026
Architecting Bioregeneration
Architecture is the shaping of space for human life — thoughtful, intentional, purposeful. Conexeu applies the same discipline to the body itself.
Conexeu
Conexeu Sciences
June 7, 2026
CXU MOA
How the CXU™ platform works: one patented extracellular matrix formulation and one device, designed to scale across multiple markets without reformulation.
Conexeu
Conexeu Sciences
May 21, 2026
B.R.E.A.S.T.
Conexeu Sciences introduces B.R.E.A.S.T.™, a 3D-bioprinted breast matrix built on the CXU™ platform and designed to advance reconstruction beyond implant-based replacement.
Conexeu
Conexeu Sciences
March 18, 2026
Conexeu Sciences: A Message from the CEO
A message from President and CEO Miles Harrison on what Architecting Bioregeneration™ means for the company and the patients it aims to serve.
Conexeu
Conexeu Sciences
March 11, 2026
About Conexeu
An introduction to Conexeu Sciences and its patented bioregenerative extracellular matrix platform, CXU™, built on more than a decade of university research.
Conexeu
August 11, 2026
Conexeu to Present at 2026 Controversies & Conversations in Laser & Cosmetic Surgery Symposium on the Role of the Extracellular Matrix in Tissue Regeneration
Conexeu Sciences Inc. (Nasdaq: CNXU) announced today that Dr. Brian Pilcher, Ph.D., Chief Medical Officer of Conexeu Sciences, will present at the Controversies & Conversations in Laser & Cosmetic Surgery Symposium, taking place Aug. 14–16, 2026.
Conexeu
July 14, 2026
The GLP-1s Are Creating Another Boom, a New $2 Billion Opportunity Exists in Aesthetics. Conexeu Is Building for It.
Conexeu Sciences is aiming CXU™ at the largest unclaimed frontier in injectable aesthetics: restoring body fullness at a scale today's fillers were never built to reach. The move builds on the company's completed 12-month P.R.O.O.F.™ preclinical study.
Conexeu
July 7, 2026
A $190 Billion Weight-Loss Boom Has Exposed a Tissue-Restoration Gap Today’s Injectables Were Not Built to Fill
Conexeu Completes 12-Month Preclinical P.R.O.O.F Study, Supporting Its Intended Move Into the $11 Billion Medical Aesthetics Market as a Platform¹
Conexeu
June 25, 2026
Conexeu Sciences Opens Vancouver R&D Facility to Advance Regenerative Tissue Platform
Nasdaq-Listed Biotech Pioneer Among the First Companies to Operate at adMare's New M4 Innovation Centre
Conexeu
June 15, 2026
Conexeu Expands Board, Executive, and Advisory Leadership With Five Appointments Post Nasdaq Listing
Board expansion from six to nine directors and the appointment of a Chief Commercial Officer and an advisory board member to help accelerate growth and strengthen execution
Conexeu
June 8, 2026
Conexeu Sciences Reports Manufacturing Scale Up and Regulatory Progress for Lead CXU™ Wound Care Program
Activities are intended to support regulatory testing and the Company’s planned first-quarter 2027 FDA 510(k) premarket notification submission
Conexeu
June 3, 2026
Conexeu Sciences to Ring Nasdaq Bell on June 10, 2026
Conexeu Sciences Inc. (Nasdaq: CNXU) ("Conexeu" or the "Company"), a biotechnology company advancing tissue regeneration, will ring the Nasdaq Closing Bell on Wednesday, June 10, 2026, at the Nasdaq MarketSite in New York City in celebration of its recent public listing and the commencement of trading under the ticker symbol "CNXU."
Conexeu
May 27, 2026
Conexeu Sciences Initiates Preclinical Development Program for B.R.E.A.S.T.™ Bioregenerative Matrix Platform with Wake Forest Institute for Regenerative Medicine
Conexeu to leverage WFIRM's advanced tissue-organ bioprinting infrastructure to evaluate the durability, integration, and resorbability of proprietary CXU™ 3D-printed matrix technology
Conexeu
May 21, 2026
Conexeu Sciences Commences Trading on Nasdaq Under Ticker Symbol “CNXU”
Public listing marks key milestone as Conexeu advances proprietary CXU™ platform and vision for regenerative medicine focused on biological restoration
Conexeu
May 19, 2026
Conexeu Sciences Advances 3D Biofabricated Matrix to Move Breast Reconstruction Beyond Implants
Conexeu’s B.R.E.A.S.T.™ was developed using the Company’s proprietary CXU™ regenerative tissue platform to support gradual tissue remodeling
Conexeu
https://www.newsfilecorp.com/release/297413/Conexeu-Sciences-Unveils-Defining-Commitment-Architecting-BioregenerationTM
May 14, 2026
Conexeu Sciences Unveils Defining Commitment: Architecting Bioregeneration™
Conexeu Sciences has made a deep commitment to the research, development, and infrastructure required to lead the next era of regenerative medicine, bringing together the Company's platform science and multi-application vision under one unifying idea, drawn from the discipline of architecture itself.
Conexeu
January 28, 2026
Why the GLP-1 Boom Demands a New Aesthetic Playbook
GLP-1s are now part of nearly every healthcare conversation and central to the obesity care landscape. In aesthetics, they are creating new demand for regenerative approaches that address soft-tissue changes associated with rapid weight loss.
Miles Harrison
October 16, 2025
Conexeu Sciences Closes Maximum $5M Reg CF Financing
Conexeu Sciences, Inc. closes a $5M Regulation Crowdfunding (Reg CF) financing round.
Conexeu
November 3, 2025
Conexeu Sciences Appoints Miles Harrison as President & Chief Executive Officer, To Shape the Future of True Tissue Regeneration
Miles D. Harrison joins Conexeu Sciences, Inc. as President & CEO.
Conexeu
November 5, 2025
Conexeu Sciences Inc. Expands Board of Directors with the Appointments of Dr. Aaron Farberg and Dr. Sebastian Purcell
Conexeu Sciences, Inc. appoints Aaron Farberg, M.D. and Sebastian Purcell, Ph.D. to its Board of Directors.
Conexeu
November 20, 2025
Conexeu Sciences Signals a Major Breakthrough in ‘Personalized Human Tissue Creation’
Conexeu Sciences Inc. achieved a defining milestone in regenerative medicine with the first ever 3D-printed structures made entirely from its patented, functional extracellular matrix (ECM).
Conexeu
SEE ALL RESOURCES
IMPORTANT NOTICES: CXU™ is a medical device candidate in preclinical development. It has not been submitted to or reviewed by the U.S. Food and Drug Administration. Safety and effectiveness have not been established. See Forward-Looking Cautionary Statement.Terms such as 'next-generation,' 'advanced,' 'innovative,' and 'bioregenerative' reflect the Company's assessment of its technology relative to existing approaches and are not intended as representations of regulatory status, clinical performance, or guaranteed commercial outcomes. CXU™ is an investigational medical device candidate. Safety and effectiveness have not been established. See Forward-Looking Cautionary Statement.

Contact Us

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
© 2026 Conexeu. All Rights Reserved.
CXU ScienceOur PlatformResources
About UsContactInvestors
Privacy PolicyTerms & Conditions